Armstrong CM - Search Results

1

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.

Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC. Lombard AP, et al. Among authors: armstrong cm. Mol Cancer Ther. 2018 Oct;17(10):2197-2205. doi: 10.1158/1535-7163.MCT-17-1269. Epub 2018 Jun 11. Mol Cancer Ther. 2018. PMID: 29891490 Free PMC article.

2

Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.

Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC. Liu C, et al. Prostate. 2015 Sep;75(13):1341-53. doi: 10.1002/pros.23015. Epub 2015 May 13. Prostate. 2015. PMID: 25970160 Free PMC article.

3

Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.

Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao AC. Zhu Y, et al. Clin Cancer Res. 2015 Sep 15;21(18):4133-42. doi: 10.1158/1078-0432.CCR-15-0269. Epub 2015 May 20. Clin Cancer Res. 2015. PMID: 25995342 Free PMC article.

4

Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

Armstrong CM, Gao AC. Armstrong CM, et al. Am J Clin Exp Urol. 2015 Aug 8;3(2):64-76. eCollection 2015. Am J Clin Exp Urol. 2015. PMID: 26309896 Free PMC article. Review.

5

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.

Liu C, Armstrong C, Zhu Y, Lou W, Gao AC. Liu C, et al. Oncotarget. 2016 May 31;7(22):32210-20. doi: 10.18632/oncotarget.8493. Oncotarget. 2016. PMID: 27049719 Free PMC article.

6

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC. Liu C, et al. Among authors: armstrong cm. Mol Cancer Ther. 2017 Jan;16(1):35-44. doi: 10.1158/1535-7163.MCT-16-0186. Epub 2016 Oct 28. Mol Cancer Ther. 2017. PMID: 27794047 Free PMC article.

7

CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer.

Armstrong CM, Gao AC. Armstrong CM, et al. J Cell Commun Signal. 2017 Mar;11(1):89-91. doi: 10.1007/s12079-017-0378-6. Epub 2017 Mar 2. J Cell Commun Signal. 2017. PMID: 28255661 Free PMC article.

8

MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.

Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC. Armstrong CM, et al. Prostate. 2017 Jun;77(9):1020-1028. doi: 10.1002/pros.23358. Prostate. 2017. PMID: 28485104 Free PMC article.

9

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC. Liu C, et al. Among authors: armstrong cm. Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12. Mol Cancer Ther. 2017. PMID: 28500234 Free PMC article.

10

Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.

Armstrong CM, Gao AC. Armstrong CM, et al. Asian J Urol. 2016 Oct;3(4):185-194. doi: 10.1016/j.ajur.2016.08.001. Epub 2016 Aug 22. Asian J Urol. 2016. PMID: 28642838 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

205 results

Search Page

Filters